On the other hand, subgroup analysis indicated that significant differences in 3-year survival rate between mesenchymal CD8-positive and CD8-negative patients when categorized by the following variables: early tumor stage (66.7% vs. 0%, p = 0.014), positive ascite fluid (62.5% vs. 0%, p = 0.014), heterologous subtype (0% vs. 75.0%, p = 0.048), small tumor volume (55.6% vs. 0%, p = 0.001) and bilateral tumors (50.0% vs. 0%, p = 0.063). Here, CD8A is linked to neoplasm.